Phase 2 data for VK2735 looks good, but Phase 3 results are long-dated (2027), making it a long-term play.

A bearish sentiment was expressed, with the speaker stating, 'I think Viking is kind of cooked, man,' implying its positive run may be over.

Mentioned as a liked small-cap biotech name that could be an M&A target, potentially leading to sharp stock price increases.

Identified as a key player and a company 'to watch' for investors looking to gain exposure to the GLP-1 theme.

Faces potential headwinds as the speaker believes the weight-loss drug sector is 'over' due to struggles from market leader Novo Nordisk.